Cwm LLC Buys 67,487 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Cwm LLC boosted its stake in OPKO Health, Inc. (NASDAQ:OPK) by 961.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,503 shares of the biotechnology company’s stock after acquiring an additional 67,487 shares during the period. Cwm LLC’s holdings in OPKO Health were worth $124,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cerity Partners LLC bought a new position in OPKO Health in the first quarter worth approximately $36,000. Capital Advisors Inc. OK increased its position in shares of OPKO Health by 133.3% during the 1st quarter. Capital Advisors Inc. OK now owns 350,000 shares of the biotechnology company’s stock valued at $581,000 after purchasing an additional 200,000 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in OPKO Health in the first quarter valued at about $139,000. PFG Investments LLC increased its position in OPKO Health by 4.9% in the first quarter. PFG Investments LLC now owns 1,217,360 shares of the biotechnology company’s stock worth $2,021,000 after buying an additional 56,475 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in OPKO Health by 158.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 74,706 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 45,798 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on OPK. JPMorgan Chase & Co. assumed coverage on OPKO Health in a report on Friday, April 25th. They issued a “neutral” rating on the stock. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $2.75.

OPKO Health Price Performance

OPK stock opened at $1.35 on Wednesday. The company has a market capitalization of $1.07 billion, a PE ratio of -19.28 and a beta of 1.34. OPKO Health, Inc. has a one year low of $1.21 and a one year high of $2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.28 and a current ratio of 2.49. The company’s fifty day moving average price is $1.34 and its 200-day moving average price is $1.48.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The company’s revenue was down 13.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.12) EPS. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.